Is Pazopanib on the market?

Pazopanib(Pazopanib) is a small molecule inhibitor of multiple protein tyrosine kinases with potential anti-tumor activity. It is used to treat patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have received chemotherapy. Pazopanib was developed by GlaxoSmithKline and was approved by the U.S. Food and Drug Administration (FDA) on October 19, 2009. It is sold under the trade name Votrient.

Pazopanib is a synthetic indazolyl pyrimidine with a steady-state concentration of 15 μg/ml. This concentration is high enough to observe maximal inhibition of VEGFR2 phosphorylation and some antitumor activity (the concentration required to inhibit the receptor is 0.01-0.084 μmol/L). Reduced tumor blood flow, increased tumor cell apoptosis, tumor growth inhibition, reduced tumor interstitial fluid pressure, and cancer cell hypoxia were observed in treated patients.

PazopanibThe original drug has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be around 3,000 yuan. The price of pazopanib original drug specifications200mg*30 tablets marketed overseas may be around 1,000 RMB per box (the price may fluctuate due to exchange rates). There are also pazopanib generic drugs produced in other countries. The price of 200mg*30 tablets produced by Bangladesh pharmaceutical factory may be around 500 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.